



Formulary 2 Updates June 11, 2025

The following drug products were reviewed and acted upon by the CDPHP Pharmacy and Therapeutics Committee for The Formulary 2.

ACA Covered under the Affordable Healthcare Act-no member cost share

MNPA Medical Necessity Prior Authorization

PA Prior authorization required

PD Preventive Drug

QL Quantity Limits Apply

SP Restricted to ConnectRx or CVS Caremark Specialty Pharmacy

ST Step Therapy

Drug	Previous Coverage	Coverage
Aptiom oral tablets 200mg (eslicarbazepine)	Tier 3, PA, PD	Not covered for new starts; current utilizers grandfathered until renewal after 7/1/2025
Brilinta oral tablets (ticagrelor)	Tier 2, PD	Not covered for new starts; current utilizers grandfathered until renewal after 7/1/2025
eltrombopag olamine oral tablets and packets (generic for Promacta)	New to Market	Tier 3, PA, QL
eslicarbazepine oral tablets (generic for Aptiom) 200, 400, 600, 800mg	New to Market	Tier 3, QL, PD
Gomekli® (mirdametinib) oral capsules or tablets	New to market	T3, QL, PA
Grafapex® (treosulfan) intravenous solution	New to market	Medical Benefit
Onapgo™ (apomorphine) subcutaneous injection	New to market	T3, QL, PA
Promacta oral tablets and packets (eltrombopag olamine)	Tier 3, PA	Not covered for new starts; current utilizers grandfathered until renewal after 7/1/2025
Romvimza™ (vimseltinib) oral capsules	New to market	T3, QL, PA
Ryoncil® (remestemcel-L-rknd) intravenous infusion	New to market	Medical Benefit, PA
ticagrelor oral tablets (generic for Brilinta)	New to market	Tier 1, QL, PD
Vanrafia™ (atrasentan) oral tablets	New to market	T3, QL, PA
Vykat™ XR (diazoxide choline) oral tablets	New to market	T3, QL, PA
Zunvey® (benzgalantamine) oral tablets	New to market	Not Covered
Zevtera™ (ceftobiprole medocartil) intravenous infusion	New to market	Medical Benefit